Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AbbVie (NY: ABBV ) 168.62 +2.06 (+1.24%) Streaming Delayed Price Updated: 12:46 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about AbbVie < Previous 1 2 3 4 5 6 7 Next > BioNTech Is Ripe For A Rebound In 2023 March 27, 2023 BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. Via MarketBeat Topics Intellectual Property Exposures COVID-19 Intellectual Property These 3 Dividend Growers Yield More Than the 10-Year Note March 22, 2023 Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment. Via MarketBeat Topics Bonds Exposures Debt Markets Healthcare Stocks With at Least 30 Years of Dividend Increases March 14, 2023 Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. Via MarketBeat Diversify Your Income with These 2 High-Yielding Dividend ETFs March 14, 2023 Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust Via MarketBeat Topics ETFs How to Pick the Best Dividend Stocks March 07, 2023 A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article. Via MarketBeat Topics Economy Exposures Interest Rates The Stock That Tripled in a Day...And May Not Be Done March 07, 2023 Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios? Via MarketBeat Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor March 02, 2023 Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. Via MarketBeat Analyst Confidence in Eli Lilly Boosted by Product Pipeline February 22, 2023 Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. Via MarketBeat Johnson & Johnson: Taking The Bull By The Horns? February 21, 2023 Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Via MarketBeat Topics Intellectual Property Regulatory Compliance Exposures Intellectual Property Legal Regulatory MarketBeat Week in Review – 2/13 - 2/17 February 18, 2023 Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week Via MarketBeat Topics Economy Exposures Interest Rates How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula February 17, 2023 New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. Via MarketBeat AbbVie Has a Mixed Outlook After Mixed Earnings February 13, 2023 AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold Via MarketBeat Topics Earnings Intellectual Property Exposures Financial Intellectual Property Is the Pain Over for Baudax Bio Investors after a 70% Spike? January 25, 2023 Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. Via MarketBeat AbbVie Stock: Dividend King ABBV Overview January 19, 2023 Via MarketBeat 4 High-Yield Dividend Kings For 2023 January 16, 2023 These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors. Via MarketBeat AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets January 06, 2023 From Immunome, Inc. Via Business Wire Harpoon Therapeutics Remains Volatile After Promising News December 14, 2022 Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. Via MarketBeat Optimism Building for Advancing Pancreatic Cancer Treatment Therapies December 01, 2022 EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END Via FinancialNewsMedia Exposures Product Safety MarketBeat: Week in Review 11/14 – 11/18 November 19, 2022 This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news. Via MarketBeat Topics Economy Workforce Exposures Economy Interest Rates Layoff One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID November 17, 2022 Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... Via FinancialNewsMedia Exposures COVID-19 Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? November 16, 2022 Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. Via MarketBeat Topics Intellectual Property Exposures Intellectual Property MarketBeat: Week in Review 10/31-11/4 November 05, 2022 You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week Via MarketBeat Topics Economy Exposures Interest Rates Why is AbbVie Stock Falling, but Still Good Long-Term? October 31, 2022 Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock. Via MarketBeat Topics Intellectual Property Exposures Intellectual Property As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops October 28, 2022 AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm... Via PressReach Topics Economy Exposures Economy Interest Rates Merck Nears Breakout Point After October Surprise Good News October 19, 2022 Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. Via MarketBeat Topics Stocks Exposures US Equities Does J&J Have Enough Alpha to Be a Solid Low Beta Stock? October 19, 2022 JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain Via MarketBeat Topics Economy Exposures Economy Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors September 29, 2022 Via AB Newswire CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member September 02, 2022 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Product Safety CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member September 02, 2022 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Product Safety Should AbbVie Inc. Have a Place in Your Dividend Portfolio? August 26, 2022 Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs. Via MarketBeat < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.